MWNA
EVFM

Marshall Wace North America’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Marshall Wace North America’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-6
Closed – – 1774
2019
Q1 		$0 Buy
+6
New +$325 ﹤0.01% 2016

Other funds holding EVFM

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TWMP
Taylor Wealth Management Partners Boston, Massachusetts $176M AUM 14.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Marshall Wace North America's EVFM Position: Q2 2019 in Review

Marshall Wace North America sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2019, closing a stake of 6 shares.

Marshall Wace North America first reported a position in EVFM in Q1 2019 and held it in 1 quarter. The position peaked at $0 in Q1 2019. 36 funds tracked by Wall St. Rank hold EVFM as of Q2 2019.

  • Marshall Wace North America reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Marshall Wace North America sold 6 Evofem Biosciences, Inc. Common Stock shares in Q2 2019.
  • Marshall Wace North America first reported a position in Evofem Biosciences, Inc. Common Stock in Q1 2019 and held it in 1 quarter.
  • Marshall Wace North America's Evofem Biosciences, Inc. Common Stock position peaked at $0 in Q1 2019.
  • 36 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2019.

Based on Marshall Wace North America's 13F filing for Q2 2019, filed 14 Aug 2019.